STEGLUJAN 5 mg/1

Steglujan 5 mg/1 combines ertugliflozin and sitagliptin for managing type 2 diabetes. This oral medication supports blood sugar control as part of a broader treatment plan.

Steglujan 5 mg/1 is a combination of ertugliflozin and sitagliptin, designed to help manage type 2 diabetes. It works by improving blood sugar levels, often used alongside diet and exercise. This medication is intended for adults with type 2 diabetes who require dual therapy. Always consult a healthcare provider to determine if this medication is suitable for your condition.

Common effects of Steglujan 5 mg/1 may include urinary tract infections, genital fungal infections, and hypoglycemia when combined with insulin or sulfonylureas. Some users may experience gastrointestinal discomfort or dizziness. Individual responses can vary, and not everyone will experience these effects.

Handle Steglujan 5 mg/1 with care, especially if you have a history of kidney issues, pancreatitis, or severe gastrointestinal diseases. Stay hydrated to reduce the risk of urinary tract infections. Monitor blood sugar levels regularly and follow your healthcare provider's advice for optimal management.

Steglujan 5 mg/1 may interact with certain medications, including insulin, sulfonylureas, and diuretics. Alcohol consumption should be limited, as it can affect blood sugar levels. Inform your healthcare provider about all medications you are taking to avoid potential interactions.